The CerviLenz team will be exhibiting at booth #1828 at the American Congress of Obstetricians and Gynecologists Annual Clinical Meeting in New Orleans, LA from May 5-8, 2013. The biggest news since last year’s meeting is publication of the ACOG Practice Bulletin No. 130 “Prediction and Prevention of Preterm Birth” last October. Universal cervical length screening is sure to be a hot topic at the meeting and at the CerviLenz booth. We will be featuring the ReachMD Preterm Birth Series, including the lastest interview with Dr. David Stone, an obstetrician who has adopted universal screening in his practice using the CerviLenz device and TVU follow-up as indicated.
Cervilenz Inc. is pleased to announce presentation of new data from an independent study at the Society for Maternal-Fetal Medicine (SMFM) Annual Meeting in San Francisco on February 15th. The study – “CerviLenz and ultrasound evaluation of cervimetry: a comparative study” 1 – adds to the body of evidence validating the efficacy of the CerviLenz® device as a first line screen for generalists to identify patients who may benefit from referral for transvaginal ultrasound (TVU).
The independent research was conducted in the clinical departments of Dr. Gian Carlo Di Renzo at the University of Perugia and Dr. Fabio Facchinetti at the University of Modena and Reggio Emilia in Italy.
“The results of this study show that CerviLenz and TVU measurements of cervical length were highly correlated with high sensitivity, specificity, and negative predictive value in both asymptomatic and symptomatic patients,“said Dr. Francesca Ferrari, the lead author.
Cervilenz Inc. and ReachMD (Sirius/XM Satellite Radio Channel 167) partner on education about preterm birth prevention. The ReachMD Preterm Birth Series addresses new professional society practice guidelines along with strategies to speed adoption and ensure access to risk assessment and treatment for all pregnant women. The first two expert interviews in the three part series are “A Change in Prenatal Care: Universal Screening for Short Cervix and Vaginal Progesterone Intervention” and “The CerviLenz Solution: Putting Cervical Length Screening into Practice for All Singleton Pregnancies.” The third expert interview will launch in early 2013.
In a turning point for obstetrics, all three professional societies published new practice guidelines recommending vaginal progesterone for asymptomatic singletons with a cervical length 20 mm or less mid-pregnancy. SMFM published a Clinical Guideline in May, ACNM published a Position Statement in June, and ACOG published a Practice Bulletin in October. Cervilenz Inc. applauds the societies’ efforts to drive adoption of this proven intervention and is committed to funding educational programs that advances our mission of helping reduce the tragic rate of preterm birth.
To celebrate World Prematurity Day, Cervilenz Inc. provided an independent educational grant to Omnia Education to support an online CME activity on the new practice guidelines. The free course is titled, “Prevention of Preterm Birth: The Critical Role of Cervical Measurement and Vaginal Progesterone,” and features Dr. Roberto Romero and Dr. Jason Baxter.
Cervilenz Inc. was featured at the 2012 Northeast Ohio Entrepreneur Expo & JumpStart Community Meeting held on November 13, 2012 at Cleveland State University’s Wolstein Center. Cervilenz Inc. exhibited alongside 117 of the region’s startups in the healthcare, cleantech, business and consumer, information technology, and support sectors.
JumpStart’s 2012 Annual Community Report also profiled Cervilenz Inc. In the accompanying video and story, Dean Koch, President and CEO of Cervilenz Inc., and Dr. Rosalyn Baxter-Jones, inventor of the CerviLenz device, discuss how CerviLenz is “A Simple Solution to Help Save Lives.”
JumpStart Ventures is an investor of Cervilenz Inc.
Get announcements and research updates, learn more about how obstetricians and midwives are using the CerviLenz device, and interact with us and your colleagues. Plus, get all the latest news on preterm birth risk assessment, cervical length measurement, high risk patient management, therapies such as progesterone, and more!